{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:42:46Z","timestamp":1790170966069,"version":"4.1.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pharmthera.2021.107866","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T18:14:57Z","timestamp":1619115297000},"page":"107866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know"],"prefix":"10.1016","volume":"226","author":[{"given":"Reem","family":"Odi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto William","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Gallily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107866_bb0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-3-642-38664-0_15","article-title":"Serotonin transporter and serotonin receptors","volume":"218","author":"Adnot","year":"2013","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107866_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0054166","article-title":"Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs","volume":"8","author":"Afrikanova","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1021\/acsmedchemlett.9b00497","article-title":"In defense of secondary pharmaceutical patents in drug discovery and development","volume":"11","author":"Agranat","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrd915","article-title":"Putting chirality to work: The strategy of chiral switches","volume":"1","author":"Agranat","year":"2002","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s12035-018-1140-7","article-title":"Cocaine blocks effects of hunger hormone, ghrelin, via interaction with neuronal Sigma-1 receptors","volume":"56","author":"Aguinaga","year":"2019","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0035","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM198511283132219","article-title":"Treatment of self-induced photosensitive epilepsy with fenfluramine","volume":"313","author":"Aicardi","year":"1985","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb6000","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.158.4.9802113","article-title":"Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.","volume":"158","author":"Archer","year":"1998","journal-title":"American Journal of Respiratory Crtical Care Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0040","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0045","first-page":"342","article-title":"Fenfluramine response in high and low functioning autistic children","volume":"26","author":"August","year":"1987","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0050","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1111\/bph.13981","article-title":"The role of 5-HT2B receptors in mitral valvulopathy: Bone marrow mobilization of endothelial progenitors","volume":"174","author":"Ayme-Dietrich","year":"2017","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.phrs.2018.09.009","article-title":"Serotonin contribution to cardiac valve degeneration: New insight for novel therapies?","volume":"140","author":"Ayme-Dietrich","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40263-020-00755-z","article-title":"Fenfluramine for the treatment of Dravet syndrome and Lennox-Gastaut syndrome","volume":"34","author":"Balagura","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0065","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-18-0596","article-title":"The melanocortin pathway and control of appetite-progress and therapeutic implications","volume":"241","author":"Baldini","year":"2019","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/npp.2010.173","article-title":"Deconstructing antiobesity compound action: Requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects","volume":"36","author":"Banas","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0075","series-title":"Medical toxicology of drug abuse: Synthesized chemicals and Psychactive plants","first-page":"255","article-title":"Serotoninergic and mixed agents","author":"Barceloux","year":"2012"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#","article-title":"Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications","volume":"36","author":"Baumann","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0085","first-page":"42S","article-title":"The absorption and urinary excretion in man of fenfluramine and its main metabolite","volume":"19","author":"Beckett","year":"1967","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.2042-7158.1972.tb08987.x","article-title":"The absorption, metabolism and elimination of (\u00b1)-N- (2-benzoyloxyethy1)norfenfluramine (JP992) in man","volume":"24","author":"Beckett","year":"1972","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF01486969","article-title":"Fenfluramine treatment of autism: Relationship of treatment response to blood levels of fenfluramine and norfenfluramine","volume":"17","author":"Beeghly","year":"1987","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0031-6989(80)80142-1","article-title":"Effect of fenfluramine and norfenfluramine stereoisomers on stimulant effects of d-amphetamine and apomorphine in the rat","volume":"12","author":"Bendotti","year":"1980","journal-title":"Pharmacological Research Communications"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0105","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/0006-2952(87)90608-3","article-title":"Neuroleptic-like effects of the l-isomer of fenfluramine on striatal dopamine release in freely moving rats","volume":"36","author":"Bettini","year":"1987","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0110","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/epi.16726","article-title":"Progress report on new antiepileptic drugs: A summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0120","first-page":"1061","article-title":"Derivatives of N-hydroxyfenfluramine and their anorectic activity","volume":"39","author":"Bianchi","year":"1984","journal-title":"Il Farmaco (Edizione Scientifica)"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-973781","article-title":"Add-on therapy of fenfluramine in intractable self-induced epilepsy","volume":"27","author":"Boel","year":"1996","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.neulet.2011.05.011","article-title":"Serotonin mediated changes in corticotropin releasing factor mRNA expression and feeding behavior isolated to the hypothalamic paraventricular nuclei","volume":"498","author":"Boisvert","year":"2011","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects","volume":"57","author":"Boyd","year":"2019","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/hrt.70.6.537","article-title":"Primary pulmonary hypertension and fenfluramine use","volume":"70","author":"Brenot","year":"1993","journal-title":"British Heart Journal"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0145","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jps.2600570717","article-title":"Fenfluramine metabolism","volume":"57","author":"Bruce","year":"1968","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF03189414","article-title":"Pharmacokinetics of fenfluramine enantiomers in man","volume":"4","author":"Caccia","year":"1979","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00547426","article-title":"Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days","volume":"29","author":"Caccia","year":"1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0922-4106(94)90102-3","article-title":"[3H](+)-pentazocine binding to rat brain sigma 1 receptors","volume":"266","author":"Cagnotto","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jpba.2017.07.008","article-title":"The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds","volume":"147","author":"Calcaterra","year":"2018","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1528-1157.2002.casa432.x","article-title":"Fenfluramine as a potential antiepileptic drug","volume":"43","author":"Casaer","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.608001","article-title":"NPY and gene therapy for epilepsy: How, when, and ... Y","volume":"13","author":"Cattaneo","year":"2021","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0180","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0185","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0190","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.13407","article-title":"Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine","volume":"57","author":"Ceulemans","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0195","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14740338.2020.1806234","article-title":"The risk of cardiovascular complications with current obesity drugs","volume":"19","author":"Chao","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0200","first-page":"684","article-title":"The pharmacokinetics of dexfenfluramine in obese and non-obese subjects","volume":"39","author":"Cheymol","year":"1995","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/2229-516X.112233","article-title":"A review of drug isomerism and its significance","volume":"3","author":"Chhabra","year":"2013","journal-title":"International Journal of Applied & Basic Medical Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107866_bb0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2006.02.129","article-title":"Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression","volume":"1087","author":"Choi","year":"2006","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0220","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with flenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0225","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.rvsc.2015.03.020","article-title":"Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease","volume":"100","author":"Cremer","year":"2015","journal-title":"Research in Veterinary Science"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0230","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.drudis.2020.04.021","article-title":"Chiral switches of chloroquine and hydroxychloroquine: Potential drugs to treat Covid-19","volume":"25","author":"D\u2019Acquarica","year":"2020","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: An analysis of 5743 individuals","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0240","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/molecules24040809","article-title":"The pharmaceutical industry in 2018. An analysis of FDA drug approvals from the perspective of molecules","volume":"24","author":"De la Torre","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0245","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/molecules25030745","article-title":"The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules","volume":"25","author":"De la Torre","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0250","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cvr\/cvt064","article-title":"Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension","volume":"99","author":"Dempsie","year":"2013","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0255","series-title":"74th annual meeting of the American Epilepsy Society, virtual meeting, December 4-8, 2020","article-title":"Fenfluramine to treat convulsive seizures in patients with CDKL5 deficiency disorder","author":"Devinsky","year":"2020"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107866_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0068-15.2015","article-title":"Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of Dravet syndrome","volume":"2","author":"Dinday","year":"2015","journal-title":"eNeuro"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/bmj.283.6296.881","article-title":"Pulmonary hypertension and fenfluramine","volume":"283","author":"Douglas","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/rr181","article-title":"Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: Lessons for the future in pathogenesis","volume":"3","author":"Eddahibi","year":"2002","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0275","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","article-title":"Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension","volume":"108","author":"Eddahibi","year":"2001","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0280","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1067\/mlc.2002.122181","article-title":"Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?","volume":"139","author":"Eddahibi","year":"2002","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0285","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0140-6736(91)92983-9","article-title":"Dexfenfluramine","volume":"337","author":"Editorial","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0290","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: An update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0295","author":"EMA (European Medicines Agency), Committee for Medicinal Products for Human Use (CHMP)"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0300","author":"EMA (European Medicines Agency), Committee for Medicinal Products for Human Use (CHMP)"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0305","series-title":"73rd annual meeting of the American Epilepsy Society, Baltimore, MD, December 6-10, 2019","article-title":"New insights into the early mechanisms underlying epileptogenesis in a zebrafish model of Dravet syndrome (Abst. 1.019)","author":"Esguerra","year":"2019"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0315","series-title":"Prescribing information (U.S.)","author":"Fintepla\u00ae","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0310","series-title":"2.2 mg\/ml oral solution. Summary of product characteristics (European prescribing information)","author":"Fintepla","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.CIR.99.1.156","article-title":"Aminorex to fen\/Phen an epidemic foretold","volume":"99","author":"Fishman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0325","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0330","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/pds.3213","article-title":"Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France","volume":"21","author":"Fournier","year":"2012","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0335","doi-asserted-by":"crossref","unstructured":"Frachon, I., Etienne, Y., Jobic,Y., Le Gal, G., Humbert, M., Leroyer, C. et al. (2010). Benfluorex and unexplained valvular heart disease: A case-control study. PLoS One 5, e10128.","DOI":"10.1371\/journal.pone.0010128"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0340","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0091-3057(88)90089-5","article-title":"Mechanisms of effects of D-fenfluramine on brain serotonin metabolism in rats: Uptake inhibition versus release","volume":"30","author":"Fuller","year":"1988","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0345","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.clinthera.2018.05.013","article-title":"The lack of effect of food on the pharmacokinetics of ZX008 (fenfluramine oral solution): Results of a single-dose, two-period crossover study","volume":"40","author":"Gammaitoni","year":"2018","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107866_bb0355","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1185\/03007997909117488","article-title":"Biochemical pharmacology of the anorectic drug fenfluramine: A review","volume":"6","author":"Garattini","year":"1979","journal-title":"Current Medical Research and Opinion"},{"issue":"suppl","key":"10.1016\/j.pharmthera.2021.107866_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0195-6663(86)80050-2","article-title":"Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system","volume":"7","author":"Garattini","year":"1986","journal-title":"Appetite"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0370","first-page":"2024","article-title":"Efficacy of fenfluramine for the treatment of compulsive behavior disorders in psychotic children [in French]","volume":"13","author":"Gastaut","year":"1984","journal-title":"Presse M\u00e9dicale"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0375","first-page":"414","article-title":"Antiepileptic effects of fenfluramine: Pilot study","volume":"22","author":"Gastaut","year":"1987","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0380","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1528-1157.2000.tb00273.x","article-title":"Fenfluramine blocks low-Mg2+\u2212 induced epileptiform activity in rat entorhinal cortex","volume":"41","author":"Gentsch","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0385","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.14822","article-title":"Fenfluramine as antiseizure medicatuion of epilepsy","author":"Gogou","year":"2021","journal-title":"Developmental Medicine and Child Neurology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0390","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cvr\/cvx092","article-title":"Serotonin and catecholamines in the development and progression of heart valve diseases","volume":"113","author":"Goldberg","year":"2017","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0395","series-title":"Servier report number 93-5792-001, dated 8\/9\/1993","article-title":"The pharmacokinetics of the metabolites of benfluorex in chronic administration: Comparison of a sustained release formulation (500 mg) with control form (3X150 mg) in human volunteers","author":"Gordon","year":"1993"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0400","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(94)00766-Z","article-title":"The 5-HT1B receptor mediates the effect of d-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y","volume":"274","author":"Grignaschi","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0405","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1111\/bph.13195","article-title":"Allosteric modulation of sigma-1 receptors elicits anti-seizure activities","volume":"172","author":"Guo","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0410","first-page":"454","article-title":"Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents","volume":"9","author":"Hafizi","year":"2000","journal-title":"The Journal of Heart Valve Disease"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0415","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2165\/11596680-000000000-00000","article-title":"Serotonergic anti-obesity agents: Past experience and future prospects","volume":"71","author":"Halford","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0420","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.yebeh.2012.10.009","article-title":"Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?","volume":"26","author":"Hamid","year":"2013","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0425","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00008571-199810000-00007","article-title":"Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: Role of CYP2D6 and 1A2","volume":"8","author":"Haritos","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0435","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.2042-7158.1982.tb04670.x","article-title":"Effect of (+)- or (\u2212)-enantiomers of fenfluramine or norfenfluramine on nutrient selection by rats","volume":"34","author":"Hirsch","year":"1982","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0440","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2261-3-5","article-title":"Risk of valvular heart disease associated with use of fenfluramine","volume":"3","author":"Hopkins","year":"2003","journal-title":"BMC Cardiovascular Disorders"},{"issue":"6098","key":"10.1016\/j.pharmthera.2021.107866_bb0445","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bmj.2.6098.1322","article-title":"Plasma fenfluramine levels, weight loss, and side effects","volume":"2","author":"Innes","year":"1977","journal-title":"British Medical Journal"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0450","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(86)90633-3","article-title":"D- and L-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat","volume":"120","author":"Invernizzi","year":"1986","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0455","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(89)90464-0","article-title":"Effects of the l-isomer of fenfluramine on dopamine mechanisms in rat brain: Further studies","volume":"164","author":"Invernizzi","year":"1989","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0460","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200629040-00001","article-title":"Safety of drug therapies used for weight loss and treatment of obesity","volume":"29","author":"Ioannides-Demos","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0465","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568026053386980","article-title":"Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs","volume":"5","author":"Isaac","year":"2005","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0470","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-013-0067-4","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: An update","volume":"52","author":"Italiano","year":"2013","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0475","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation","volume":"339","author":"Jick","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0480","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.yebeh.2005.07.014","article-title":"The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant","volume":"7","author":"Jobe","year":"2005","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107866_bb0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-9149(99)00281-7","article-title":"Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota","volume":"84","author":"Kimmel","year":"1999","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0490","series-title":"Poster presentation.. 74th annual meeting of the American Epilepsy Society, Virtual Meeting, December 4\u20138, 2020","article-title":"Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: A randomized, double-blind, placebo-controlled clinical trial","author":"Knupp","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0495","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/epi.14540","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"59","author":"Lagae","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0500","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0505","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0510","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/0024-3205(83)90764-6","article-title":"Serotonin mediation of the protective effect of clonidine against pentylenetetrazol-induced seizures in rats","volume":"32","author":"Lazarova","year":"1983","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0515","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: Clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0520","series-title":"72st annual meeting of the American Epilepsy Society, New Orleans, LA, November 30\u2013December 4, 2018","article-title":"Antiepileptic effect of the enantiomers of fenfluramine and norfenfluramine in a Dravet zebrafish model. [abstract no.]","author":"Li","year":"2018"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0525","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.ijo.0801020","article-title":"Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy","volume":"23","author":"Li","year":"1999","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0530","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJM199608293350910","article-title":"Pharmacotherapy for obesity: Do the benefits outweigh the risks?","volume":"335","author":"Manson","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2021.107866_bb0535","first-page":"S25","article-title":"SCN1A\/Na(V) 1.1 channelopathies: Mechanisms in expression systems, animal models, and human iPSC models","volume":"60","author":"Mantegazza","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0540","doi-asserted-by":"crossref","first-page":"106989","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin","year":"2020","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0545","series-title":"73rd annual meeting of the American Epilepsy Society, Baltimore, MD, December 6-10, 2019. Abstract (Abst. 2.203)","article-title":"Evaluation of the acute anticonvulsant efficacy of fenfluramine in mouse models of acute and chronic seizures","author":"Martin","year":"2019"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0550","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09059180.00003313","article-title":"Drug-induced pulmonary arterial hypertension: A recent outbreak","volume":"22","author":"Montani","year":"2013","journal-title":"European Respiratory Review"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0555","first-page":"747","article-title":"Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo","volume":"127","author":"Morita","year":"1983","journal-title":"The American Review of Respiratory Disease"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0560","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/diacare.29.03.06.dc05-1439","article-title":"Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18-week, randomized, double-blind study","volume":"29","author":"Moulin","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0565","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(11)60334-6","article-title":"Mediator scandal rocks French medical community","volume":"377","author":"Mullard","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0570","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: A randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0575","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0192623317690609","article-title":"Regulatory forum review: Utility of in vitro secondary pharmacology data to assess risk of drug-induced valvular heart disease in humans: Regulatory considerations","volume":"45","author":"Papoian","year":"2017","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0580","first-page":"467","article-title":"Fenfluramine-phentermine is associated with an increase in cellular proliferation ex vivo and in vitro","volume":"26","author":"Rajamannan","year":"2017","journal-title":"The Journal of Heart Valve Disease"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0585","first-page":"827","article-title":"Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects","volume":"10","author":"Rajamannan","year":"2001","journal-title":"The Journal of Heart Valve Disease"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0590","series-title":"The metabolism and kinetics of fenfluramine, its optical isomers and a structural analogue, benfluorex","author":"Richards","year":"1985"},{"issue":"129","key":"10.1016\/j.pharmthera.2021.107866_bb0595","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1523\/JNEUROSCI.4056-03.2004","article-title":"Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus","volume":"24","author":"Richichi","year":"2004","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0600","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/jc.2018-01010","article-title":"Cardiovascular safety during and after use of phentermine and topiramate","volume":"104","author":"Ritchey","year":"2019","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0605","doi-asserted-by":"crossref","first-page":"23373","DOI":"10.18632\/oncotarget.25169","article-title":"Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors","volume":"9","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107866_bb5000","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0091-3057(01)00669-4","article-title":"Serotonin releasing agents. Neurochemical, therapeutic and adverse effects","volume":"71","author":"Rothman","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0610","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expert Opinion in Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0615","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MJT.0b013e31817fde95","article-title":"Appetite suppressants, cardiac valve disease and combination pharmacotherapy","volume":"16","author":"Rothman","year":"2009","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0620","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0625","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0630","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/jpet.103.049684","article-title":"(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters","volume":"305","author":"Rothman","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0635","first-page":"327","article-title":"Sigma receptors [sigmaRs]: Biology in normal and diseased states","volume":"36","author":"Rousseaux","year":"2016","journal-title":"Journal of Receptor and Signal Transduction Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0640","series-title":"Mechanisms of biogenic amine neurotransmitter transporters in: Neurotransmitter transporters: Structure, function, and regulation","author":"Rudnik","year":"1997"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0645","first-page":"291","article-title":"Clinical-pharmacological study with the two isomers (d-, l-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: Blood levels, EEG mapping and safety evaluation","volume":"15","author":"Saletu","year":"1993","journal-title":"Methods and Findings in Experimental and Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0650","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0028-3908(89)90080-4","article-title":"Evidence that central 5-HT2 receptors do not play an important role in the anorectic activity of D-fenfluramine in the rat","volume":"28","author":"Samanin","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0655","series-title":"Fen-Phen case lawyers say they'll reject Wyeth offer","author":"Saul","year":"2005"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0660","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","article-title":"Obesity pharmacotherapy","volume":"102","author":"Saunders","year":"2018","journal-title":"The Medical Clinics of North America"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0665","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1183\/09031936.00188611","article-title":"Pulmonary hypertension associated with benfluorex exposure","volume":"40","author":"Savale","year":"2012","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0670","series-title":"74th annual meeting of the American Epilepsy Society, Virtual Meeting, December 4\u20138, 2020","article-title":"Efficacy and tolerability of adjunctive FINTEPLA (Fenfluramine hydrochloride) in an open-label extension study of Dravet syndrome patients treated for up to 3 years (Abst. 978)","author":"Scheffer","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0675","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/cpt.1469","article-title":"An old drug for a new indication: Repurposing fenfluramine from an anorexigen to an antiepileptic drug","volume":"106","author":"Schoonjans","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0680","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1756285615607726","article-title":"Low-dose fenfluramine in the treatment of neurologic disorders: Experience in Dravet syndrome","volume":"8","author":"Schoonjans","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0685","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","article-title":"Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: A review of its benefit-risk profile in a new patient population","volume":"33","author":"Schoonjans","year":"2017","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0690","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0026-895X(25)13357-9","article-title":"Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters","volume":"44","author":"Schuldiner","year":"1993","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0695","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/mol.104.009266","article-title":"Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor","volume":"68","author":"Setola","year":"2005","journal-title":"Molecular Pharmacology"},{"issue":"5930","key":"10.1016\/j.pharmthera.2021.107866_bb0700","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/bmj.3.5930.576-b","article-title":"Letter: Fenfluramine and psychosis","volume":"3","author":"Shannon","year":"1974","journal-title":"British Medical Journal,"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0705","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-3565(24)37472-5","article-title":"5-Hydroxytryptamine 2 receptor facilitates GABAergic neurotransmission in rat hippocampus","volume":"285","author":"Shen","year":"1998","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0710","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acschemneuro.8b00739","article-title":"Evaluation of selective 5-HT2C agonists in acute seizure models","volume":"10","author":"Silenieks","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0715","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/17512433.2020.1703109","article-title":"Efficacy and safety of lorcaserin in obesity: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107866_bb0720","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1345\/aph.1R501","article-title":"Phentermine\/topiramate for the treatment of obesity","volume":"47","author":"Smith","year":"2013","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0725","series-title":"71st annual meeting of the American Epilepsy Society, Washington DC, December 1-5, 2017a","article-title":"Fenfluramine in the treatment of drug-resistant seizures: Back-translation using zebrafish and mice. (Abst. 1.275)","author":"Sourbron","year":"2017"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0730","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acschemneuro.5b00342","article-title":"Serotonergic modulation as effective treatment for Dravet syndrome in a zebrafish mutant model","volume":"7","author":"Sourbron","year":"2016","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0735","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fphar.2017.00191","article-title":"Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish","volume":"8","author":"Sourbron","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0740","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00104807","article-title":"Pulmonary arterial hypertension associated with fenfluramine exposure: Report of 109 cases","volume":"31","author":"Souza","year":"2008","journal-title":"The European Respiratory Journal"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107866_bb0745","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/epi.16690","article-title":"Efficacy and safety of fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study","volume":"61","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107866_bb0750","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/epi.16474","article-title":"Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome","volume":"61","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0755","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","article-title":"National trends in antiobesity medication use","volume":"163","author":"Stafford","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0765","series-title":"74th annual meeting of the American Epilepsy Society, Virtual Meeting, December 4\u20138, 2020","article-title":"Fenfluramine (FINTEPLA) in Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial (Study 3) (Abs. 853)","author":"Sullivan","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0760","series-title":"74th annual meeting of the American Epilepsy Society, Virtual Meeting, December 4\u20138, 2020b","article-title":"Fenfluramine (FINTEPLA) in Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial (Study 3)","author":"Sullivan","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0770","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0775","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/pds.3642","article-title":"Adverse effects of benfluorex on heart valves and pulmonary circulation","volume":"23","author":"Szymanski","year":"2014","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0780","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(02)01751-X","article-title":"Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine","volume":"445","author":"Tao","year":"2002","journal-title":"European Journal of Pharmacology"},{"issue":"15 Supplement","key":"10.1016\/j.pharmthera.2021.107866_bb0785","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1212\/WNL.94.15_supplement.4274","article-title":"Safety and efficacy of Add-on ZX008 (fenfluramine hydrochloride oral solution) in sunflower syndrome: An open-label pilot study of 5 patients","volume":"94","author":"Thiele","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0790","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(00)02047-X","article-title":"Chiral switches","volume":"355","author":"Tucker","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0795","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/epi.14658","article-title":"Fenfluramine, a serotonin-releasing drug, prevents seizure-induced respiratory arrest and is anticonvulsant in the DBA\/1 mouse model of SUDEP","volume":"60","author":"Tupal","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0800","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0006-2952(00)00306-3","article-title":"Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors","volume":"59","author":"Ulus","year":"2000","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0805","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1211\/0022357001773689","article-title":"The effect of fenfluramine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rat lung: A comparison with chlorphentermine","volume":"52","author":"Valodia","year":"2000","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0810","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbr.2017.04.008","article-title":"The activity of selective sigma-1 receptor ligands in seizure models in vivo","volume":"328","author":"Vavers","year":"2017","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0815","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fphar.2019.00223","article-title":"Allosteric modulators of sigma-1 receptor: A review","volume":"10","author":"Vavers","year":"2019","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb6005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0028-3908(01)00063-6","article-title":"Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors","volume":"41","author":"Vickers","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0820","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2016.06.007","article-title":"Cardiovascular effects of the new weight loss agents","volume":"68","author":"Vorsanger","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0825","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/pds.2044","article-title":"Benfluorex and valvular heart disease: A cohort study of a million people with diabetes mellitus","volume":"19","author":"Weill","year":"2010","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0830","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0835","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/01.CIR.94.9.2216","article-title":"Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction","volume":"94","author":"Weir","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0840","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.ijo.0800920","article-title":"Synergistic interactions between fenfluramine and phentermine","volume":"23","author":"Wellman","year":"1999","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0845","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.clinthera.2018.07.009","article-title":"Fenfluramine: Back from the dead","volume":"40","author":"Wurtman","year":"2018","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0850","series-title":"A poster, presented at Zogenix scientific exhibit during the 70th AES annual meeting December 2-6, 2016","article-title":"Extrapolating of fenfluramine pharmacokinetics from adults to children: Estimating PK exposure in patients with Dravet syndrome","author":"Zhang","year":"2016"},{"key":"10.1016\/j.pharmthera.2021.107866_bb0855","article-title":"Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: Inhibition of epileptic seizures by the serotonin agonist fenfluramine","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:48Z","timestamp":1759011528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821000681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":169,"alternative-id":["S0163725821000681"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107866","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107866"}}